Towards Healthcare
U.S. Home Infusion Therapy Market to Advance $36.88 Bn by 2034

U.S. Home Infusion Therapy Market Advancing Patient Care and Outcomes

The U.S. home infusion therapy industry is projected to rise from USD 18.23 billion in 2024 to USD 36.88 billion by 2034, reflecting a CAGR of 7.3% over the next decade. Home infusion therapy in the U.S. lets patients receive medications like antibiotics, pain management, or nutrition through an IV at home instead of a hospital. It’s a convenient, cost-effective option for chronic conditions, reducing hospital stays while ensuring safe, professional care from nurses or pharmacists.

Category: Medical Devices Insight Code: 5102 Format: PDF / PPT / Excel

The U.S. home infusion therapy market is predicted to expand from USD 19.56 billion in 2025 to USD 36.88 billion by 2034, growing at a CAGR of 7.3% during the forecast period from 2025 to 2034.

U.S. Home Infusion Therapy Market Size 2023 - 2034

U.S. Home Infusion Therapy Market Report Highlights

  • Infusion pumps, the workhorses of the market, held a commanding 43% share in 2023.
  • Chronic diseases like cancer and diabetes drove the market in 2023, accounting for 36% of the share.
  • By product, the infusion pumps segment dominated the global market in 2024.
  • By product, the needleless connectors segment is expected to expand rapidly in the market in the coming years.
  • By application, the anti-infective segment held a major revenue share of the market in 2024.
  • By application, the endocrinology segment is expected to witness the fastest growth in the market over the forecast period.
  • In November 2024, GC Biopharma selected AOM Infusion as its limited distribution partner for ALYGLO to expand its national reach and its expertise in specialized care for chronic conditions. ALYGLO is an FDA-approved immunoglobulin replacement therapy for the treatment of primary humoral immunodeficiency (PI). It can be administered by a nurse at home or in an infusion center. (Source: Businesswire)
  • In July 2024, Shields Health Solutions announced a collaboration with UnityPoint at Home to extend a specialty pharmacy program that provides patients with complex, chronic conditions access to specialized pharma services. The partnership was made to lower costs, broaden treatment options, and improve medication management. (Source: Businesswire)

According to the American Cancer Society, approximately 1.8 million people were diagnosed with cancer, with over 600,000 people expected to die as a result of this challenging disease. Home infusion allows patients to manage cancer treatment actively, giving them greater control.

The COVID-19 pandemic hit a pause on elective surgeries, causing a dip in the need for follow-up home care. Thanks to cost-cutting by slashing inpatient stays and a buffet of infusion device options. Home infusion therapy (HIT) takes the healthcare party directly to a patient's doorstep at home, nursing home, hospital or outpatient clinic. But, also, a knowledge gap looms between the home infusion experts and the clinicians, potentially leading to less-than-stellar outcomes. Let's bridge that gap for optimal therapeutic adventures.

U.S. Home infusion therapy is like bringing the hospital to your home! It's a specialized healthcare service where patients receive medications through a needle or catheter at home instead of going to a medical facility. This method is often used for conditions requiring ongoing treatments, like infections, chronic illnesses or pain management. A trained healthcare professional usually administers the infusions, ensuring patients can comfortably manage their treatment in the familiar environment of their own homes. It offers convenience and personalized care, making the healing process a bit easier.

Key Metrics and Overview

Metric Details
Market Size in 2024 USD 18.23 Billion
Projected Market Size in 2034 USD 36.88 Billion
CAGR (2025 - 2034) 7.3%
Market Segmentation By Product and By Application
Top Key Players Option Care Health, Inc., B. Braun Medical, Inc., Baxter International Inc., Fresenius Kabi USA, Amedisys, Inc., CareCentrix, Inc.

 

Estimated Number of Cancer Survivors in the U.S., By Current Age, January, 2022

U.S. home infusion therapy has become increasingly popular, especially in cancer treatment, as it involves delivering medications directly into a patient's bloodstream through intravenous (IV) infusion within the comfort of their home. Several key factors drive this shift. The patients appreciate the comfort and convenience of receiving treatment at home, bypassing the need for frequent hospital or clinic visits. This enhances the overall quality of life for individuals undergoing prolonged or regular therapies and allows for a more personalized care approach. Healthcare professionals can better tailor the schedule and dosage of medications to suit each patient’s needs and lifestyle.

Additionally, regarding comfort and personalization, U.S. home infusion therapy reduces healthcare costs in the long run. Although there may be initial setup expenses, the overall financial burden is alleviated by fewer hospital visits, leading to decreased transportation costs, less strain on healthcare facilities and potentially lower insurance expenses. Technological advances are crucial, making administering complex therapies at home easier. Portable infusion pumps and remote monitoring capabilities enable healthcare providers to closely track a patient's progress without constant in-person visits.

Furthermore, U.S. home Infusion therapy empowers patients to manage their treatment actively, fostering an increased sense of control. This empowerment can have positive effects on the psychological and emotional well-being of individuals grappling with cancer. Moreover, avoiding infections is a significant benefit, considering hospitals can be breeding grounds for pathogens. Home infusion minimizes the risk of exposure to harmful infections, which is particularly crucial for patients with compromised immune systems, such as those undergoing cancer treatment. While the prevalence of cancer has fueled the growth of the home infusion therapy market, its appeal extends beyond oncology to encompass other chronic conditions requiring ongoing intravenous treatments. This trend underscores a broader shift towards patient-centric healthcare, aiming to enhance medical interventions' effectiveness and overall experience.

Innovation Increases Adoption of Elastomeric Devices

Imagine a world where receiving medical treatments becomes more comfortable and efficient. Elastomeric devices, essentially flexible and stretchy gadgets, are being innovated to make home infusion therapies easier to adopt. These devices use intelligent materials that can adapt to the body's movements, providing a user-friendly experience for patients undergoing infusion therapies. The goal is to enhance comfort and convenience and encourage more people to embrace these important medical treatments.

The Elastomeric Pump Device, offered by Balmers Pump, serves diverse purposes in drug delivery, catering to needs such as administering antibiotics, chemotherapeutic drugs, analgesics and local anesthetics. Its applications span various medical fields, including postoperative analgesia, ambulatory chemotherapy and outpatient parenteral antibiotic therapy (OPAT). Post-surgery, these pumps effectively manage acute pain and improve the patient's quality of life by maintaining optimal drug plasma levels. Ambulatory chemotherapy enables patients to receive infusions comfortably at home, ensuring adherence to treatment regimens without disrupting daily routines. Additionally, Elastomeric Pumps contribute to the growth of outpatient parenteral antibiotic therapy (OPAT) services, offering cost-effective, user-friendly solutions that enhance patient mobility and streamline the overall care process. As a result, these applications contribute to the global expansion of the market for Elastomeric Pump Devices.

Challenges Occur due to Healthcare Policies

The U.S. home infusion therapy market faces a friendly challenge with healthcare policies. Currently, these policies mainly support treatments in hospitals or clinics, making it a bit tricky for home infusion to become more widespread. The rules and how insurance pays for things favor treatments in healthcare buildings. These policies might only partially show how excellent home infusion therapy is. We need our healthcare rules to be more open and friendly towards this convenient way of getting treatment at home. Our healthcare guidelines need an update to fully embrace the great possibilities of home infusion therapy.

Segmental Insights

Which Product Segment Dominated the U.S. Home Infusion Therapy Market?

By product, the infusion pumps segment held a dominant presence in the market in 2024. This segment dominated because infusion pumps are an essential component of infusion therapy to deliver medications or other fluids. The availability of ambulatory infusion pumps boosts the segment’s growth. They are portable and wearable pumps and can be used by patients anywhere. Technological advancements have led to the development of smart pumps with safety features, including user alerts. The pump can alert the user about any adverse reaction or dose maintenance.

By product, the needleless connectors segment is expected to grow at the fastest CAGR in the market during the forecast period. The increasing risk of needlestick infections necessitates healthcare professionals to use needleless connectors. Needleless connectors are devices that allow quick access to the infusion line, ensuring a secure connection. The medications and fluids are directly administered to the patient through catheters. They are widely used as they are safer with reduced complications.

Why Did the Anti-Infective Segment Dominate the U.S. Home Infusion Therapy Market?

By application, the anti-infective segment held the largest share of the market in 2024. This is due to the rising prevalence of infectious diseases and the need for targeted delivery. They are used in different types of diseases, such as pneumonia, meningitis, sepsis, herpes, cytomegalovirus, candidiasis, etc. At-home anti-infective infusion therapy allows patients to avoid hospitalizations for severe infections. This approach delivers medications directly into the bloodstream, supporting the body’s healing process.

By application, the endocrinology segment is expected to grow with the highest CAGR in the market during the studied years. The rising cases of diabetes and other endocrine disorders facilitate the need for home infusion therapy. The most common therapies include hormone therapy, such as testosterone, estrogen, and insulin. This therapy works by lowering the amount of hormones in the body or by blocking their action. According to the International Diabetes Federation, approximately 589 million people were living with diabetes in 2024. (Source: https://idf.org/about-diabetes/diabetes-facts-figures/)

Geographical Landscape

The geographical landscape for the U.S. home infusion therapy market varies, with growth observed in both developed and developing regions. In developed countries like the United States and Western European nations, an aging population and a preference for home-based healthcare contribute to market expansion. Developing regions, driven by improving healthcare infrastructure and rising awareness, also show increasing adoption of home infusion services. Regulatory frameworks, reimbursement policies and each region's healthcare landscape may influence market dynamics. The National Home Infusion Association (NHIA) estimated that approximately 3.2 million people receive home infusion services in the U.S. annually. (Source: NHIF)

Estimated Number of New Cases for Selected Cancer in United States, 2023

Recent Developments

  • In April 2025, Duke HomeCare & Hospice announced the opening of Duke Home Infusion Pharmacy to enhance patient care and expand the number of patients served in the community. The pharmacy offers a range of infusion therapies, including antibiotics, TPN, chemotherapy drugs, and specialty medications. (Source: https://corporate.dukehealth.org/news/duke-home-infusion-pharmacy-opens)
  • In January 2025, Eisai Co. Ltd. and Biogen, Inc. announced that the U.S. FDA approved their Biologics License Application (BLA) for LEQEMBI (lecanemab-irmb) subcutaneous autoinjector for weekly maintenance dosing. The biologic is indicated for the treatment of Alzheimer’s disease with mild cognitive impairment. (Source: https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-lecanemab-irmb-biologics-license)

U.S. Home Infusion Therapy Market Companies

U.S. Home Infusion Therapy Market Companies

U.S. Home Infusion Therapy Market Segment

By Product

  • Infusion pumps
    • Insulin pumps
    • Syringe pumps
    • Elastomeric pumps
    • Patient Controlled Analgesics (PCA)
    • Volumetric Pumps
  • Intravenous Sets
  • IV Cannulas
  • Needleless Connectors

By Application

  • Anti-Infective
  • Endocrinology
    • Diabetes
    • Others
  • Hydration Therapy
    • Athletes
    • Others
  • Chemotherapy
  • Enteral Nutrition
  • Parenteral Nutrition
  • Specialty Pharmaceuticals
  • Others
  • Last Updated: 10 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services.

Learn more about Deepa Pandey

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

Home infusion therapy involves administering medications or fluids through a needle or catheter at home instead of in a hospital or clinic setting.

Infusion therapy involves delivering medications for infections, pain management or chronic diseases directly into the bloodstream. It also includes hydration for patients unable to consume enough liquids orally and nutrition support through intravenous administration of nutrients and vitamins. The blood transfusions for conditions like anemia and chemotherapy by administering cancer-fighting drugs directly into the bloodstream, effectively managing various medical conditions.

The increase in chronic disorders is one of the major reasons for the growth of the U.S. home infusion therapy market. The rise in chronic conditions requiring long-term treatment, such as cancer, diabetes and autoimmune diseases, fuels the demand for infusion therapies.

World Health Organization, National Home Infusion Foundation, Center for Disease Control and Prevention, American Cancer Society, ScienceDirect Publication.